{"gene":"BTF3","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1990,"finding":"BTF3 forms a stable complex with RNA polymerase II. Two isoforms exist: BTF3a (27 kDa, transcriptionally active) and BTF3b (lacking the first 44 residues of BTF3a, transcriptionally inactive despite retaining RNA pol II binding ability).","method":"Protein purification, cDNA cloning, in vitro complex formation assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — original biochemical purification combined with cDNA cloning and functional characterization; foundational study replicated by subsequent work","pmids":["2320128"],"is_preprint":false},{"year":1992,"finding":"The BTF3 gene contains seven exons; BTF3a and BTF3b are products of alternative splicing from the same gene. A putative TATA box(es) and CAAT box were identified in the promoter region.","method":"Genomic cloning, cDNA library screening, sequence analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization, single lab, sequence-based evidence with functional implication","pmids":["1386332"],"is_preprint":false},{"year":1992,"finding":"Yeast homolog of BTF3 (EGD1/Egd1p) stabilizes the Gal4p transcriptional activator-DNA complex (gel retardation assay); loss of EGD1 reduces galactose-regulated gene induction, placing BTF3 homolog as a co-activator facilitating transcription factor-DNA interaction.","method":"Filter binding, footprinting, gel retardation, gene disruption, purification","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical assays (footprinting, gel retardation, purification) combined with genetic loss-of-function in yeast","pmids":["1448098"],"is_preprint":false},{"year":1994,"finding":"Yeast BTF3 homologs (Egd1p and Btt1p) have redundant functions; double deletion elevates GAL1, GAL10, ACT1, and SSO1 mRNA levels (RNA pol II transcribed genes) but not rRNA or tRNA, indicating a negative regulatory role on RNA pol II transcription.","method":"Gene disruption, mRNA expression analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via double-mutant analysis, single lab, consistent with ortholog data","pmids":["8052529"],"is_preprint":false},{"year":1995,"finding":"Homozygous disruption of the BTF3 gene in mice causes lethality at embryonic day ~6.5 (early postimplantation), establishing BTF3 as essential for early postimplantation development.","method":"Retroviral gene trap insertional mutagenesis, germline transmission, embryo analysis","journal":"Transgenic research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function in vivo with specific developmental phenotype; germline knockout confirmed","pmids":["7655515"],"is_preprint":false},{"year":1999,"finding":"BTF3a is phosphorylated in vitro by the CK2 α2β2 holoenzyme (but not by α or α' alone), and physically interacts with CK2 subunit β both in yeast two-hybrid and GST pulldown/co-immunoprecipitation assays, identifying BTF3a as a CK2 substrate requiring the β subunit for recognition.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, in vitro kinase assay","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro phosphorylation assay plus two binding methods (yeast two-hybrid and GST pulldown/co-IP), single lab","pmids":["10094400"],"is_preprint":false},{"year":2007,"finding":"BTF3 silencing in pancreatic cancer cells down-regulates cancer-associated genes (EPHB2, ABL2, HPSE2, ATM) and up-regulates others (KRAG, RRAS2, NF-κB, etc.) without affecting chemotherapy- or radiotherapy-induced apoptosis, supporting a role as a transcriptional regulator rather than direct apoptosis modulator in this context.","method":"siRNA knockdown, DNA microarray analysis, cell growth and apoptosis assays","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function combined with transcriptome-wide readout; single lab","pmids":["17312387"],"is_preprint":false},{"year":2019,"finding":"BTF3 stabilizes BMI1 protein in prostate cancer cells; BTF3 loss reduces BMI1 levels and impairs cancer stem-like self-renewal and metastatic potential, while BTF3 overexpression promotes these traits.","method":"Gain- and loss-of-function (ectopic overexpression and shRNA), in vitro and in vivo tumorigenic/stemness assays, immunofluorescence","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple phenotypic readouts; single lab; stabilization mechanism not fully biochemically resolved","pmids":["31138311"],"is_preprint":false},{"year":2020,"finding":"BTF3 knockdown in TNBC cells increases BMI1 protein degradation, leading to de-repression of IRF7 transcription and activation of the Type I interferon signaling pathway, linking BTF3-mediated stemness to immune evasion.","method":"shRNA knockdown, bioinformatics, western blot, transcriptional reporter analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — loss-of-function with mechanistic pathway readout; partially dependent on bioinformatics; single lab","pmids":["33383560"],"is_preprint":false},{"year":2021,"finding":"BTF3b (but not BTF3a) transcriptionally upregulates RFC (Replication Factor C) family subunit genes involved in DNA replication and damage repair; BTF3 knockdown reduces RFC expression, attenuates DNA replication, impairs DNA damage repair, and increases G2/M arrest. RFC3 knockdown diminishes the growth advantage conferred by BTF3b overexpression.","method":"Isoform-specific overexpression/knockdown, reporter assay, cell cycle analysis, DNA damage assay, in vitro and in vivo cisplatin sensitivity","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific functional dissection with rescue experiment (RFC3 KD epistasis), multiple assays, single lab","pmids":["33414468"],"is_preprint":false},{"year":2021,"finding":"BTF3 transcriptionally targets CHD1L (identified by RNA-seq + ChIP-seq); BTF3 also interacts with proteins in the nascent-polypeptide-associated complex (NAC) and may inhibit E3 ubiquitin ligase HERC2-mediated p53 degradation (identified by IP-MS and E3 ligase analysis).","method":"RNA-seq, ChIP-seq, immunoprecipitation-mass spectrometry, E3 ubiquitin ligase analysis","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — orthogonal genomic and proteomic methods (ChIP-seq + IP-MS); HERC2/p53 part less functionally validated in abstract; single lab","pmids":["33644029"],"is_preprint":false},{"year":2021,"finding":"BTF3 regulates BMI1 expression in colorectal cancer; BMI1 overexpression partially rescues stem cell-like traits and EMT after BTF3 knockdown, placing BTF3 upstream of BMI1 in control of CRC stemness and epithelial-mesenchymal transition.","method":"siRNA knockdown, rescue overexpression, BMI1 inhibitor (PTC-209) treatment, stemness assays (CD133, colony formation, tumorosphere), EMT marker expression","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via rescue experiment; multiple phenotypic assays; single lab; consistent with prostate cancer findings","pmids":["34293363"],"is_preprint":false},{"year":2018,"finding":"BTF3 regulates ESR1 (ERα) transcriptional expression in luminal breast cancer cells; BTF3 knockdown reduces ERα-dependent transcription and sensitizes ER+ cells to PI3Kα inhibitor BYL-719 both in vitro and in vivo.","method":"shRNA knockdown, transcriptional reporter assay, gene expression analysis, in vitro and in vivo drug sensitivity assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with mechanistic transcriptional readout and in vivo validation; single lab","pmids":["30315845"],"is_preprint":false},{"year":2023,"finding":"BTF3 directly interacts with FOXM1 in HCC cells (co-immunoprecipitation) and transcriptionally activates FOXM1; BTF3 knockdown reduces FOXM1 and GLUT1 expression, attenuating glycolysis (ECAR, glucose consumption, lactate production). FOXM1 overexpression rescues glycolytic activity in BTF3-knockdown cells.","method":"Co-immunoprecipitation, dual-luciferase reporter assay, siRNA knockdown, FOXM1 rescue overexpression, XF96 extracellular flux analysis, xenograft model","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus luciferase reporter plus rescue epistasis experiment; single lab; in vivo confirmation","pmids":["37382415"],"is_preprint":false},{"year":2024,"finding":"BTF3 forms a complex with STAT3 in monocytes (co-immunoprecipitation); this BTF3/STAT3 complex promotes STAT3 phosphorylation, which activates NLRP3 promoter-driven pyroptosis and apoptosis. BTF3 depletion inhibits STAT3 phosphorylation and suppresses pyroptosis.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter, RNA immunoprecipitation, RNA pull-down, CRISPR/siRNA knockdown, flow cytometry","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal binding and functional assays; single lab; specific cellular context (monocytes/APS)","pmids":["38224186"],"is_preprint":false},{"year":2019,"finding":"BTF3a knockdown (CRISPR/Cas9) in THP-1-derived macrophages increases autophagy flux and lysosomal targeting of Mycobacterium tuberculosis-containing autophagosomes, resulting in enhanced intracellular Mtb clearance. Mtb infection upregulates BTF3a expression in macrophages.","method":"CRISPR/Cas9 knockdown, LC3B-II turnover assay, LAMP1 expression, confocal microscopy (LC3B/lysotracker/Rab7 colocalization), CFU assay","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR loss-of-function with multiple functional readouts (autophagy flux, colocalization, bacterial burden); single lab","pmids":["30684544"],"is_preprint":false},{"year":2024,"finding":"BTF3 transcriptionally upregulates PDCD2L in hepatocellular carcinoma; PDCD2L in turn restrains the p53 pathway to promote proliferation and inhibit apoptosis. BTF3 knockdown inhibits proliferation and promotes apoptosis in HCC cells.","method":"Knockdown experiments, transcriptional analysis, cell function assays (proliferation, apoptosis), p53 pathway readout","journal":"Molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanism inferred from knockdown and expression correlation; PDCD2L as direct transcriptional target not fully validated by ChIP or reporter in abstract; single lab","pmids":["39707202"],"is_preprint":false},{"year":2025,"finding":"BTF3 is recruited by LINC00622 lncRNA to the RRAGD promoter to transcriptionally enhance RRAGD expression, activating mTORC1 and suppressing autophagic cell death in cutaneous melanoma.","method":"ChIP, co-immunoprecipitation, reporter assays, loss-of-function knockdown, in vitro and in vivo tumor models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms promoter recruitment; epistasis via mTORC1 readout; single lab","pmids":["40651979"],"is_preprint":false},{"year":2025,"finding":"RPL18 stabilizes BTF3 mRNA, increasing BTF3 protein levels and downstream STAT3 activation, promoting melanoma proliferation, migration, and temozolomide resistance. Pharmacologic STAT3 inhibition reverses RPL18-dependent oncogenic phenotypes.","method":"Melanoma cell lines, patient-derived organoids, xenograft models, STAT3 inhibitor treatment, mRNA stability assay (implied), western blot","journal":"iScience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mRNA stabilization mechanism not rigorously biochemically resolved in abstract; single lab; post-translational/mRNA-level mechanism not fully validated","pmids":["41550725"],"is_preprint":false},{"year":2019,"finding":"BTF3 knockdown in osteosarcoma (Saos-2) cells activates STAT3, S6 ribosomal protein, HSP27, and SAPK/JNK2 (all inhibited by BTF3 silencing), while SAPK/JNK1 is upregulated, identifying these as signaling mediators downstream of BTF3.","method":"Lentivirus shRNA knockdown, PathScan Intracellular Signaling Array, flow cytometry, colony formation assay","journal":"Journal of Cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — signaling array readout without mechanistic follow-up; single lab; indirect pathway association","pmids":["31205542"],"is_preprint":false}],"current_model":"BTF3 is a general transcription factor that forms a stable complex with RNA polymerase II and exists as two alternatively spliced isoforms (BTF3a, transcriptionally active; BTF3b, lacking 44 N-terminal residues and transcriptionally inactive yet still RNA pol II-binding); it is essential for early postimplantation mouse development, acts as an oncogenic transcription factor that directly upregulates targets including RFC subunits, FOXM1/GLUT1, CHD1L, ESR1 (ERα), and PDCD2L, recruits to chromatin via lncRNA partners (e.g., LINC00622) to activate RRAGD/mTORC1 signaling, stabilizes BMI1 protein to sustain cancer stem-like traits, forms a complex with STAT3 to enhance its phosphorylation and downstream signaling, is phosphorylated by CK2 holoenzyme (requiring the β subunit), and in macrophages suppresses autophagic clearance of intracellular Mycobacterium tuberculosis."},"narrative":{"mechanistic_narrative":"BTF3 is a basal transcription-associated factor that forms a stable complex with RNA polymerase II and functions as a transcriptional co-regulator, with two alternatively spliced isoforms—the active BTF3a and the truncated, RNA pol II-binding but transcriptionally inactive BTF3b lacking the N-terminal 44 residues [PMID:2320128, PMID:1386332]. Its co-regulatory role is conserved: the yeast homologs Egd1p/Btt1p stabilize activator–DNA complexes yet redundantly restrain RNA pol II-transcribed gene output, while BTF3a is a CK2 substrate recognized through the CK2 β subunit [PMID:1448098, PMID:8052529, PMID:10094400]. BTF3 is essential for early postimplantation mouse development, with homozygous disruption causing embryonic lethality around E6.5 [PMID:7655515]. Across cancers BTF3 acts as an oncogenic transcriptional driver, directly or indirectly upregulating targets that span proliferation, metabolism, and stemness programs: BTF3b activates RFC subunit genes to sustain DNA replication and damage repair [PMID:33414468], and BTF3 transcriptionally activates CHD1L, ESR1/ERα, FOXM1 (driving GLUT1-dependent glycolysis), and the autophagy regulator RRAGD upon recruitment by the lncRNA LINC00622 to activate mTORC1 [PMID:33644029, PMID:30315845, PMID:37382415, PMID:40651979]. BTF3 also operates post-transcriptionally by stabilizing BMI1 protein to maintain cancer stem-like self-renewal and EMT, with BMI1 loss de-repressing IRF7 and Type I interferon signaling [PMID:31138311, PMID:33383560, PMID:34293363]. In addition, BTF3 forms a complex with STAT3 and enhances its phosphorylation and downstream signaling [PMID:38224186]. Beyond oncogenesis, BTF3a is induced by Mycobacterium tuberculosis in macrophages where it suppresses autophagic clearance of the pathogen [PMID:30684544].","teleology":[{"year":1990,"claim":"Established BTF3 as a polypeptide that stably associates with RNA polymerase II and exists as two isoforms differing in transcriptional competence, defining its identity as a basal transcription-associated factor.","evidence":"Protein purification, cDNA cloning and in vitro complex formation assay defining BTF3a (active) versus BTF3b (inactive, pol II-binding)","pmids":["2320128"],"confidence":"High","gaps":["Did not resolve the structural basis by which the N-terminal 44 residues confer transcriptional activity","Did not map the contact surface with RNA pol II"]},{"year":1992,"claim":"Demonstrated that the two isoforms arise by alternative splicing from a single seven-exon gene, explaining the molecular origin of BTF3a/BTF3b.","evidence":"Genomic cloning and sequence analysis of the BTF3 locus","pmids":["1386332"],"confidence":"Medium","gaps":["Did not establish how splicing between isoforms is regulated","Promoter element function only inferred from sequence"]},{"year":1992,"claim":"Showed via the yeast ortholog that BTF3-family proteins act as co-activators stabilizing transcription factor–DNA complexes, providing a conserved mechanistic role.","evidence":"Footprinting, gel retardation, purification and EGD1 gene disruption in yeast","pmids":["1448098"],"confidence":"High","gaps":["Whether human BTF3 stabilizes specific activator–DNA complexes was not directly tested","Direct DNA-binding contribution of BTF3 itself unresolved"]},{"year":1994,"claim":"Refined the co-regulator picture by showing the redundant yeast homologs negatively regulate RNA pol II transcription specifically, distinguishing pol II from pol I/III targets.","evidence":"Double gene disruption (Egd1p/Btt1p) with mRNA expression profiling in yeast","pmids":["8052529"],"confidence":"Medium","gaps":["Activator versus repressor balance in human cells not addressed","Mechanism of negative regulation not defined"]},{"year":1995,"claim":"Established BTF3 as essential for mammalian development, demonstrating a non-redundant in vivo requirement.","evidence":"Gene-trap insertional knockout in mice with embryo analysis showing E6.5 lethality","pmids":["7655515"],"confidence":"High","gaps":["Cellular cause of lethality not identified","Specific developmental transcriptional targets unknown"]},{"year":1999,"claim":"Identified BTF3a as a CK2 substrate whose phosphorylation requires the CK2 β regulatory subunit, introducing post-translational regulation of BTF3.","evidence":"Yeast two-hybrid, GST pulldown/co-IP and in vitro kinase assays with CK2 holoenzyme and subunits","pmids":["10094400"],"confidence":"Medium","gaps":["Functional consequence of CK2 phosphorylation on BTF3 activity untested","Phosphosite(s) not mapped in vivo"]},{"year":2007,"claim":"Provided the first cancer-context evidence that BTF3 functions as a transcriptional regulator of cancer-associated genes rather than a direct apoptosis modulator.","evidence":"siRNA knockdown with DNA microarray and apoptosis assays in pancreatic cancer cells","pmids":["17312387"],"confidence":"Medium","gaps":["Direct versus indirect transcriptional targets not distinguished","No promoter-binding evidence"]},{"year":2018,"claim":"Linked BTF3 to hormone-receptor signaling by showing it regulates ESR1/ERα transcription and modulates drug sensitivity in breast cancer.","evidence":"shRNA knockdown, reporter assays and in vitro/in vivo PI3Kα inhibitor sensitivity in luminal breast cancer","pmids":["30315845"],"confidence":"Medium","gaps":["Direct binding of BTF3 to the ESR1 promoter not shown","Mechanism connecting BTF3 to PI3K pathway indirect"]},{"year":2019,"claim":"Defined a post-translational oncogenic mechanism: BTF3 stabilizes BMI1 protein to sustain cancer stem-like self-renewal and metastasis.","evidence":"Reciprocal gain/loss-of-function with in vitro and in vivo stemness and tumorigenesis assays in prostate cancer","pmids":["31138311"],"confidence":"Medium","gaps":["Biochemical basis of BMI1 stabilization not resolved","Whether stabilization is direct binding or indirect"]},{"year":2019,"claim":"Implicated STAT3 and stress-kinase signaling as downstream mediators of BTF3 in osteosarcoma.","evidence":"shRNA knockdown with signaling-array profiling and colony formation in Saos-2 cells","pmids":["31205542"],"confidence":"Low","gaps":["Signaling-array associations lack mechanistic follow-up","Direct versus indirect effects on each kinase undetermined"]},{"year":2019,"claim":"Extended BTF3 function beyond cancer, showing BTF3a is induced by M. tuberculosis and suppresses autophagic bacterial clearance in macrophages.","evidence":"CRISPR/Cas9 knockdown with autophagy flux, colocalization and CFU assays in THP-1 macrophages","pmids":["30684544"],"confidence":"Medium","gaps":["Molecular mechanism by which BTF3 restrains autophagy unknown","Transcriptional targets in macrophages not identified"]},{"year":2020,"claim":"Connected BTF3-driven stemness to immune evasion, showing BTF3 loss destabilizes BMI1 and de-represses IRF7/Type I interferon signaling.","evidence":"shRNA knockdown with western blot and reporter analysis in TNBC cells","pmids":["33383560"],"confidence":"Medium","gaps":["Direct chromatin link from BMI1 to IRF7 not fully resolved here","In vivo immune consequences not tested"]},{"year":2021,"claim":"Assigned isoform-specific function by showing BTF3b activates RFC subunit genes to support DNA replication and damage repair, with RFC3 epistasis confirming the axis.","evidence":"Isoform-specific overexpression/knockdown, reporter, cell cycle, DNA damage and cisplatin sensitivity assays","pmids":["33414468"],"confidence":"Medium","gaps":["How transcriptionally inactive BTF3b activates RFC genes mechanistically unclear","Direct promoter occupancy of RFC genes not detailed"]},{"year":2021,"claim":"Identified CHD1L as a direct transcriptional target and placed BTF3 within the NAC and a potential HERC2/p53 regulatory axis.","evidence":"RNA-seq + ChIP-seq for targets and IP-MS plus E3 ligase analysis for interactions","pmids":["33644029"],"confidence":"Medium","gaps":["HERC2/p53 functional consequence not validated","NAC interaction not functionally dissected"]},{"year":2021,"claim":"Confirmed BTF3 acts upstream of BMI1 to control stemness and EMT in a second cancer type, generalizing the BTF3–BMI1 axis.","evidence":"siRNA knockdown with BMI1 rescue, BMI1 inhibitor and stemness/EMT assays in colorectal cancer","pmids":["34293363"],"confidence":"Medium","gaps":["Whether BTF3 controls BMI1 transcriptionally or post-translationally here not distinguished","EMT mechanism downstream of BMI1 not detailed"]},{"year":2023,"claim":"Demonstrated BTF3 physically interacts with and transcriptionally activates FOXM1 to drive GLUT1-dependent glycolysis, linking BTF3 to tumor metabolism.","evidence":"Co-IP, dual-luciferase reporter, siRNA knockdown with FOXM1 rescue, extracellular flux and xenograft assays in HCC","pmids":["37382415"],"confidence":"Medium","gaps":["Direct BTF3 occupancy at the FOXM1 promoter versus co-factor role not fully separated","Structural basis of BTF3–FOXM1 interaction unknown"]},{"year":2024,"claim":"Showed BTF3 forms a complex with STAT3 and promotes its phosphorylation to drive NLRP3-dependent pyroptosis, defining a direct BTF3–STAT3 signaling mechanism.","evidence":"Co-IP, ChIP, luciferase, RIP, RNA pull-down and knockdown with flow cytometry in monocytes","pmids":["38224186"],"confidence":"Medium","gaps":["How BTF3 enhances STAT3 phosphorylation mechanistically unresolved","Kinase mediating the effect not identified"]},{"year":2024,"claim":"Proposed PDCD2L as a BTF3 transcriptional target that restrains the p53 pathway to promote HCC proliferation.","evidence":"Knockdown with transcriptional and p53-pathway readouts plus proliferation/apoptosis assays","pmids":["39707202"],"confidence":"Low","gaps":["PDCD2L as a direct target not validated by ChIP or reporter","Connection to p53 pathway largely correlative"]},{"year":2025,"claim":"Established lncRNA-guided chromatin recruitment, with LINC00622 directing BTF3 to the RRAGD promoter to activate mTORC1 and suppress autophagic cell death.","evidence":"ChIP, co-IP, reporter and loss-of-function with mTORC1 readout in melanoma models","pmids":["40651979"],"confidence":"Medium","gaps":["Generality of lncRNA-directed recruitment to other targets unknown","Direct BTF3–LINC00622 binding interface not mapped"]},{"year":2025,"claim":"Identified upstream regulation of BTF3 via RPL18-mediated mRNA stabilization feeding STAT3 activation and drug resistance in melanoma.","evidence":"Melanoma cell lines, organoids, xenografts, STAT3 inhibitor treatment and mRNA stability assays","pmids":["41550725"],"confidence":"Low","gaps":["mRNA-stabilization mechanism not rigorously resolved biochemically","Directness of RPL18–BTF3 mRNA interaction unconfirmed"]},{"year":null,"claim":"How BTF3's canonical role as an RNA pol II-associated co-regulator and NAC component mechanistically connects to its diverse oncogenic transcriptional targets and post-translational stabilization of partners remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying structural model linking BTF3 chromatin recruitment to specific target selection","The biochemical basis distinguishing BTF3a versus BTF3b target specificity is undefined","Direct versus cofactor-mediated transcriptional activation not separated across most reported targets"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,9,10,13]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[14,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,10,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,10,13]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[15,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,12,13]}],"complexes":["RNA polymerase II complex","nascent-polypeptide-associated complex (NAC)","BTF3/STAT3 complex"],"partners":["STAT3","FOXM1","BMI1","CSNK2B","HERC2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00478","full_name":"Butyrophilin subfamily 3 member A3","aliases":[],"length_aa":584,"mass_kda":65.0,"function":"Plays a role in T-cell responses in the adaptive immune response","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O00478/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BTF3","classification":"Common Essential","n_dependent_lines":916,"n_total_lines":1208,"dependency_fraction":0.7582781456953642},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000145741","cell_line_id":"CID000064","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"HSPA8","stoichiometry":10.0},{"gene":"NACA","stoichiometry":10.0},{"gene":"ATG9A","stoichiometry":0.2},{"gene":"HSPH1","stoichiometry":0.2},{"gene":"TUBB","stoichiometry":0.2},{"gene":"HSPA1L","stoichiometry":0.2},{"gene":"ITPR1","stoichiometry":0.2},{"gene":"EIF4H","stoichiometry":0.2},{"gene":"TMEM263","stoichiometry":0.2},{"gene":"NACA2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000064","total_profiled":1310},"omim":[{"mim_id":"619270","title":"INTRAFLAGELLAR TRANSPORT-ASSOCIATED PROTEIN; IFTAP","url":"https://www.omim.org/entry/619270"},{"mim_id":"613595","title":"BUTYROPHILIN, SUBFAMILY 3, MEMBER A3; BTN3A3","url":"https://www.omim.org/entry/613595"},{"mim_id":"603739","title":"BASIC TRANSCRIPTION FACTOR 3 PSEUDOGENE 13; BTF3P13","url":"https://www.omim.org/entry/603739"},{"mim_id":"603738","title":"BASIC TRANSCRIPTION FACTOR 3 PSEUDOGENE 12; BTF3P12","url":"https://www.omim.org/entry/603738"},{"mim_id":"602543","title":"BASIC TRANSCRIPTION FACTOR 3 PSEUDOGENE 11; BTF3P11","url":"https://www.omim.org/entry/602543"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BTF3"},"hgnc":{"alias_symbol":["BTF3a","BTF3b"],"prev_symbol":["NACB"]},"alphafold":{"accession":"O00478","domains":[{"cath_id":"2.60.40.10","chopping":"33-145","consensus_level":"high","plddt":95.1568,"start":33,"end":145},{"cath_id":"2.60.40.10","chopping":"152-242","consensus_level":"high","plddt":89.5404,"start":152,"end":242},{"cath_id":"2.60.120.920","chopping":"326-513","consensus_level":"high","plddt":92.9639,"start":326,"end":513},{"cath_id":"1.20.5","chopping":"246-323","consensus_level":"medium","plddt":74.4891,"start":246,"end":323}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00478","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00478-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00478-F1-predicted_aligned_error_v6.png","plddt_mean":82.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTF3","jax_strain_url":"https://www.jax.org/strain/search?query=BTF3"},"sequence":{"accession":"O00478","fasta_url":"https://rest.uniprot.org/uniprotkb/O00478.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00478/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00478"}},"corpus_meta":[{"pmid":"2320128","id":"PMC_2320128","title":"Sequencing and expression of complementary DNA for the general transcription factor BTF3.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2320128","citation_count":106,"is_preprint":false},{"pmid":"7655515","id":"PMC_7655515","title":"An insertional mutation in the BTF3 transcription factor gene leads to an early postimplantation lethality in mice.","date":"1995","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/7655515","citation_count":88,"is_preprint":false},{"pmid":"17312387","id":"PMC_17312387","title":"Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17312387","citation_count":52,"is_preprint":false},{"pmid":"24386364","id":"PMC_24386364","title":"Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24386364","citation_count":44,"is_preprint":false},{"pmid":"1448098","id":"PMC_1448098","title":"The EGD1 product, a yeast homolog of human BTF3, may be involved in GAL4 DNA binding.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1448098","citation_count":43,"is_preprint":false},{"pmid":"15716105","id":"PMC_15716105","title":"Translation initiation factor (iso) 4E interacts with BTF3, the beta subunit of the nascent polypeptide-associated complex.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15716105","citation_count":42,"is_preprint":false},{"pmid":"8052529","id":"PMC_8052529","title":"Yeast BTF3 protein is encoded by duplicated genes and inhibits the expression of some genes in vivo.","date":"1994","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8052529","citation_count":41,"is_preprint":false},{"pmid":"38203709","id":"PMC_38203709","title":"Matrine Targets BTF3 to Inhibit the Growth of Canine Mammary Tumor Cells.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203709","citation_count":37,"is_preprint":false},{"pmid":"31138311","id":"PMC_31138311","title":"BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31138311","citation_count":34,"is_preprint":false},{"pmid":"1386332","id":"PMC_1386332","title":"Genomic structure of the putative BTF3 transcription factor.","date":"1992","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/1386332","citation_count":31,"is_preprint":false},{"pmid":"30315845","id":"PMC_30315845","title":"Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30315845","citation_count":26,"is_preprint":false},{"pmid":"23532689","id":"PMC_23532689","title":"Clinicopathological significance of BTF3 expression in colorectal cancer.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23532689","citation_count":23,"is_preprint":false},{"pmid":"33414468","id":"PMC_33414468","title":"BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33414468","citation_count":21,"is_preprint":false},{"pmid":"34293363","id":"PMC_34293363","title":"BTF3-mediated regulation of BMI1 promotes colorectal cancer through influencing epithelial-mesenchymal transition and stem cell-like traits.","date":"2021","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34293363","citation_count":21,"is_preprint":false},{"pmid":"27748804","id":"PMC_27748804","title":"Kahweol induces apoptosis by suppressing BTF3 expression through the ERK signaling pathway in non-small cell lung cancer cells.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27748804","citation_count":21,"is_preprint":false},{"pmid":"34416489","id":"PMC_34416489","title":"MiR-27a-5p regulates acrylamide-induced mitochondrial dysfunction and intrinsic apoptosis via targeting Btf3 in rats.","date":"2021","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34416489","citation_count":20,"is_preprint":false},{"pmid":"10094400","id":"PMC_10094400","title":"BTF3 is a potential new substrate of protein kinase CK2.","date":"1999","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10094400","citation_count":16,"is_preprint":false},{"pmid":"37382415","id":"PMC_37382415","title":"BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37382415","citation_count":16,"is_preprint":false},{"pmid":"34927409","id":"PMC_34927409","title":"Enhanced Room-Temperature Ionic Conductivity of NaCB11H12 via High-Energy Mechanical Milling.","date":"2021","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/34927409","citation_count":12,"is_preprint":false},{"pmid":"36641250","id":"PMC_36641250","title":"LncRNA-ZNF252P-AS1/miR-15b-5p promotes the proliferation of keloid fibroblast by regulating the BTF3-STAT3 signaling pathway.","date":"2022","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/36641250","citation_count":11,"is_preprint":false},{"pmid":"32582971","id":"PMC_32582971","title":"miR‑802 inhibits the epithelial‑mesenchymal transition, migration and invasion of cervical cancer by regulating BTF3.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32582971","citation_count":11,"is_preprint":false},{"pmid":"31404775","id":"PMC_31404775","title":"Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31404775","citation_count":10,"is_preprint":false},{"pmid":"33383560","id":"PMC_33383560","title":"BTF3 promotes stemness and inhibits TypeⅠInterferon signaling pathway in triple-negative breast cancer.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33383560","citation_count":9,"is_preprint":false},{"pmid":"31205542","id":"PMC_31205542","title":"BTF3 Silencing Inhibits the Proliferation of Osteosarcoma Cells.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31205542","citation_count":9,"is_preprint":false},{"pmid":"33644029","id":"PMC_33644029","title":"Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33644029","citation_count":8,"is_preprint":false},{"pmid":"38224186","id":"PMC_38224186","title":"ARID5B-mediated LINC01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the BTF3/STAT3 complex in β2GPI/anti-β2GPI-treated monocytes.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38224186","citation_count":8,"is_preprint":false},{"pmid":"9325059","id":"PMC_9325059","title":"The visual assignment of genes by fiber-fish: BTF3 protein homologue gene (BTF3) and a novel pseudogene of human RNA helicase A (DDX9P) on 13q22.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9325059","citation_count":8,"is_preprint":false},{"pmid":"23029305","id":"PMC_23029305","title":"Human beta casein fragment (54-59) modulates M. bovis BCG survival and basic transcription factor 3 (BTF3) expression in THP-1 cell line.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029305","citation_count":7,"is_preprint":false},{"pmid":"27981726","id":"PMC_27981726","title":"Transgenic tobacco plants constitutively expressing peanut BTF3 exhibit increased growth and tolerance to abiotic stresses.","date":"2017","source":"Plant biology (Stuttgart, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/27981726","citation_count":7,"is_preprint":false},{"pmid":"30684544","id":"PMC_30684544","title":"Targeted depletion of BTF3a in macrophages activates autophagic pathway to eliminate Mycobacterium tuberculosis.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30684544","citation_count":5,"is_preprint":false},{"pmid":"8809106","id":"PMC_8809106","title":"BTF3 is evolutionarily conserved in fission yeast.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8809106","citation_count":5,"is_preprint":false},{"pmid":"39278369","id":"PMC_39278369","title":"METTL3-driven m6A modification of lncRNA FAM230B suppresses ferroptosis by modulating miR-27a-5p/BTF3 axis in gastric cancer.","date":"2024","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/39278369","citation_count":4,"is_preprint":false},{"pmid":"39707202","id":"PMC_39707202","title":"BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/39707202","citation_count":2,"is_preprint":false},{"pmid":"40651979","id":"PMC_40651979","title":"LINC00622 transcriptionally promotes RRAGD to repress mTORC1-modulated autophagic cell death by associating with BTF3 in cutaneous melanoma.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40651979","citation_count":1,"is_preprint":false},{"pmid":"40389874","id":"PMC_40389874","title":"Comparative transcriptomics of transgenic tobacco plants overexpressing Miscanthus sinensis BTF3.","date":"2025","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40389874","citation_count":1,"is_preprint":false},{"pmid":"41550725","id":"PMC_41550725","title":"RPL18 promotes melanoma progression and drug resistance via BTF3/STAT3-dependent mechanisms and immune modulation.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41550725","citation_count":0,"is_preprint":false},{"pmid":"41993204","id":"PMC_41993204","title":"IGLC3- tumor cells drive chemoresistance in colorectal cancer by polarizing SPP1+ macrophages via the CD44-Wnt-BTF3 axis.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41993204","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19484,"output_tokens":4629,"usd":0.063944,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12826,"output_tokens":5516,"usd":0.101015,"stage2_stop_reason":"end_turn"},"total_usd":0.164959,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"BTF3 forms a stable complex with RNA polymerase II. Two isoforms exist: BTF3a (27 kDa, transcriptionally active) and BTF3b (lacking the first 44 residues of BTF3a, transcriptionally inactive despite retaining RNA pol II binding ability).\",\n      \"method\": \"Protein purification, cDNA cloning, in vitro complex formation assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original biochemical purification combined with cDNA cloning and functional characterization; foundational study replicated by subsequent work\",\n      \"pmids\": [\"2320128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The BTF3 gene contains seven exons; BTF3a and BTF3b are products of alternative splicing from the same gene. A putative TATA box(es) and CAAT box were identified in the promoter region.\",\n      \"method\": \"Genomic cloning, cDNA library screening, sequence analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization, single lab, sequence-based evidence with functional implication\",\n      \"pmids\": [\"1386332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Yeast homolog of BTF3 (EGD1/Egd1p) stabilizes the Gal4p transcriptional activator-DNA complex (gel retardation assay); loss of EGD1 reduces galactose-regulated gene induction, placing BTF3 homolog as a co-activator facilitating transcription factor-DNA interaction.\",\n      \"method\": \"Filter binding, footprinting, gel retardation, gene disruption, purification\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical assays (footprinting, gel retardation, purification) combined with genetic loss-of-function in yeast\",\n      \"pmids\": [\"1448098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Yeast BTF3 homologs (Egd1p and Btt1p) have redundant functions; double deletion elevates GAL1, GAL10, ACT1, and SSO1 mRNA levels (RNA pol II transcribed genes) but not rRNA or tRNA, indicating a negative regulatory role on RNA pol II transcription.\",\n      \"method\": \"Gene disruption, mRNA expression analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via double-mutant analysis, single lab, consistent with ortholog data\",\n      \"pmids\": [\"8052529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Homozygous disruption of the BTF3 gene in mice causes lethality at embryonic day ~6.5 (early postimplantation), establishing BTF3 as essential for early postimplantation development.\",\n      \"method\": \"Retroviral gene trap insertional mutagenesis, germline transmission, embryo analysis\",\n      \"journal\": \"Transgenic research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function in vivo with specific developmental phenotype; germline knockout confirmed\",\n      \"pmids\": [\"7655515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BTF3a is phosphorylated in vitro by the CK2 α2β2 holoenzyme (but not by α or α' alone), and physically interacts with CK2 subunit β both in yeast two-hybrid and GST pulldown/co-immunoprecipitation assays, identifying BTF3a as a CK2 substrate requiring the β subunit for recognition.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, in vitro kinase assay\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro phosphorylation assay plus two binding methods (yeast two-hybrid and GST pulldown/co-IP), single lab\",\n      \"pmids\": [\"10094400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BTF3 silencing in pancreatic cancer cells down-regulates cancer-associated genes (EPHB2, ABL2, HPSE2, ATM) and up-regulates others (KRAG, RRAS2, NF-κB, etc.) without affecting chemotherapy- or radiotherapy-induced apoptosis, supporting a role as a transcriptional regulator rather than direct apoptosis modulator in this context.\",\n      \"method\": \"siRNA knockdown, DNA microarray analysis, cell growth and apoptosis assays\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function combined with transcriptome-wide readout; single lab\",\n      \"pmids\": [\"17312387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BTF3 stabilizes BMI1 protein in prostate cancer cells; BTF3 loss reduces BMI1 levels and impairs cancer stem-like self-renewal and metastatic potential, while BTF3 overexpression promotes these traits.\",\n      \"method\": \"Gain- and loss-of-function (ectopic overexpression and shRNA), in vitro and in vivo tumorigenic/stemness assays, immunofluorescence\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple phenotypic readouts; single lab; stabilization mechanism not fully biochemically resolved\",\n      \"pmids\": [\"31138311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BTF3 knockdown in TNBC cells increases BMI1 protein degradation, leading to de-repression of IRF7 transcription and activation of the Type I interferon signaling pathway, linking BTF3-mediated stemness to immune evasion.\",\n      \"method\": \"shRNA knockdown, bioinformatics, western blot, transcriptional reporter analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — loss-of-function with mechanistic pathway readout; partially dependent on bioinformatics; single lab\",\n      \"pmids\": [\"33383560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTF3b (but not BTF3a) transcriptionally upregulates RFC (Replication Factor C) family subunit genes involved in DNA replication and damage repair; BTF3 knockdown reduces RFC expression, attenuates DNA replication, impairs DNA damage repair, and increases G2/M arrest. RFC3 knockdown diminishes the growth advantage conferred by BTF3b overexpression.\",\n      \"method\": \"Isoform-specific overexpression/knockdown, reporter assay, cell cycle analysis, DNA damage assay, in vitro and in vivo cisplatin sensitivity\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific functional dissection with rescue experiment (RFC3 KD epistasis), multiple assays, single lab\",\n      \"pmids\": [\"33414468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTF3 transcriptionally targets CHD1L (identified by RNA-seq + ChIP-seq); BTF3 also interacts with proteins in the nascent-polypeptide-associated complex (NAC) and may inhibit E3 ubiquitin ligase HERC2-mediated p53 degradation (identified by IP-MS and E3 ligase analysis).\",\n      \"method\": \"RNA-seq, ChIP-seq, immunoprecipitation-mass spectrometry, E3 ubiquitin ligase analysis\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — orthogonal genomic and proteomic methods (ChIP-seq + IP-MS); HERC2/p53 part less functionally validated in abstract; single lab\",\n      \"pmids\": [\"33644029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTF3 regulates BMI1 expression in colorectal cancer; BMI1 overexpression partially rescues stem cell-like traits and EMT after BTF3 knockdown, placing BTF3 upstream of BMI1 in control of CRC stemness and epithelial-mesenchymal transition.\",\n      \"method\": \"siRNA knockdown, rescue overexpression, BMI1 inhibitor (PTC-209) treatment, stemness assays (CD133, colony formation, tumorosphere), EMT marker expression\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via rescue experiment; multiple phenotypic assays; single lab; consistent with prostate cancer findings\",\n      \"pmids\": [\"34293363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BTF3 regulates ESR1 (ERα) transcriptional expression in luminal breast cancer cells; BTF3 knockdown reduces ERα-dependent transcription and sensitizes ER+ cells to PI3Kα inhibitor BYL-719 both in vitro and in vivo.\",\n      \"method\": \"shRNA knockdown, transcriptional reporter assay, gene expression analysis, in vitro and in vivo drug sensitivity assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with mechanistic transcriptional readout and in vivo validation; single lab\",\n      \"pmids\": [\"30315845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTF3 directly interacts with FOXM1 in HCC cells (co-immunoprecipitation) and transcriptionally activates FOXM1; BTF3 knockdown reduces FOXM1 and GLUT1 expression, attenuating glycolysis (ECAR, glucose consumption, lactate production). FOXM1 overexpression rescues glycolytic activity in BTF3-knockdown cells.\",\n      \"method\": \"Co-immunoprecipitation, dual-luciferase reporter assay, siRNA knockdown, FOXM1 rescue overexpression, XF96 extracellular flux analysis, xenograft model\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus luciferase reporter plus rescue epistasis experiment; single lab; in vivo confirmation\",\n      \"pmids\": [\"37382415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTF3 forms a complex with STAT3 in monocytes (co-immunoprecipitation); this BTF3/STAT3 complex promotes STAT3 phosphorylation, which activates NLRP3 promoter-driven pyroptosis and apoptosis. BTF3 depletion inhibits STAT3 phosphorylation and suppresses pyroptosis.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter, RNA immunoprecipitation, RNA pull-down, CRISPR/siRNA knockdown, flow cytometry\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal binding and functional assays; single lab; specific cellular context (monocytes/APS)\",\n      \"pmids\": [\"38224186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BTF3a knockdown (CRISPR/Cas9) in THP-1-derived macrophages increases autophagy flux and lysosomal targeting of Mycobacterium tuberculosis-containing autophagosomes, resulting in enhanced intracellular Mtb clearance. Mtb infection upregulates BTF3a expression in macrophages.\",\n      \"method\": \"CRISPR/Cas9 knockdown, LC3B-II turnover assay, LAMP1 expression, confocal microscopy (LC3B/lysotracker/Rab7 colocalization), CFU assay\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR loss-of-function with multiple functional readouts (autophagy flux, colocalization, bacterial burden); single lab\",\n      \"pmids\": [\"30684544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTF3 transcriptionally upregulates PDCD2L in hepatocellular carcinoma; PDCD2L in turn restrains the p53 pathway to promote proliferation and inhibit apoptosis. BTF3 knockdown inhibits proliferation and promotes apoptosis in HCC cells.\",\n      \"method\": \"Knockdown experiments, transcriptional analysis, cell function assays (proliferation, apoptosis), p53 pathway readout\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanism inferred from knockdown and expression correlation; PDCD2L as direct transcriptional target not fully validated by ChIP or reporter in abstract; single lab\",\n      \"pmids\": [\"39707202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BTF3 is recruited by LINC00622 lncRNA to the RRAGD promoter to transcriptionally enhance RRAGD expression, activating mTORC1 and suppressing autophagic cell death in cutaneous melanoma.\",\n      \"method\": \"ChIP, co-immunoprecipitation, reporter assays, loss-of-function knockdown, in vitro and in vivo tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms promoter recruitment; epistasis via mTORC1 readout; single lab\",\n      \"pmids\": [\"40651979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RPL18 stabilizes BTF3 mRNA, increasing BTF3 protein levels and downstream STAT3 activation, promoting melanoma proliferation, migration, and temozolomide resistance. Pharmacologic STAT3 inhibition reverses RPL18-dependent oncogenic phenotypes.\",\n      \"method\": \"Melanoma cell lines, patient-derived organoids, xenograft models, STAT3 inhibitor treatment, mRNA stability assay (implied), western blot\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mRNA stabilization mechanism not rigorously biochemically resolved in abstract; single lab; post-translational/mRNA-level mechanism not fully validated\",\n      \"pmids\": [\"41550725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BTF3 knockdown in osteosarcoma (Saos-2) cells activates STAT3, S6 ribosomal protein, HSP27, and SAPK/JNK2 (all inhibited by BTF3 silencing), while SAPK/JNK1 is upregulated, identifying these as signaling mediators downstream of BTF3.\",\n      \"method\": \"Lentivirus shRNA knockdown, PathScan Intracellular Signaling Array, flow cytometry, colony formation assay\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — signaling array readout without mechanistic follow-up; single lab; indirect pathway association\",\n      \"pmids\": [\"31205542\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTF3 is a general transcription factor that forms a stable complex with RNA polymerase II and exists as two alternatively spliced isoforms (BTF3a, transcriptionally active; BTF3b, lacking 44 N-terminal residues and transcriptionally inactive yet still RNA pol II-binding); it is essential for early postimplantation mouse development, acts as an oncogenic transcription factor that directly upregulates targets including RFC subunits, FOXM1/GLUT1, CHD1L, ESR1 (ERα), and PDCD2L, recruits to chromatin via lncRNA partners (e.g., LINC00622) to activate RRAGD/mTORC1 signaling, stabilizes BMI1 protein to sustain cancer stem-like traits, forms a complex with STAT3 to enhance its phosphorylation and downstream signaling, is phosphorylated by CK2 holoenzyme (requiring the β subunit), and in macrophages suppresses autophagic clearance of intracellular Mycobacterium tuberculosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BTF3 is a basal transcription-associated factor that forms a stable complex with RNA polymerase II and functions as a transcriptional co-regulator, with two alternatively spliced isoforms—the active BTF3a and the truncated, RNA pol II-binding but transcriptionally inactive BTF3b lacking the N-terminal 44 residues [#0, #1]. Its co-regulatory role is conserved: the yeast homologs Egd1p/Btt1p stabilize activator–DNA complexes yet redundantly restrain RNA pol II-transcribed gene output, while BTF3a is a CK2 substrate recognized through the CK2 \\u03b2 subunit [#2, #3, #5]. BTF3 is essential for early postimplantation mouse development, with homozygous disruption causing embryonic lethality around E6.5 [#4]. Across cancers BTF3 acts as an oncogenic transcriptional driver, directly or indirectly upregulating targets that span proliferation, metabolism, and stemness programs: BTF3b activates RFC subunit genes to sustain DNA replication and damage repair [#9], and BTF3 transcriptionally activates CHD1L, ESR1/ER\\u03b1, FOXM1 (driving GLUT1-dependent glycolysis), and the autophagy regulator RRAGD upon recruitment by the lncRNA LINC00622 to activate mTORC1 [#10, #12, #13, #17]. BTF3 also operates post-transcriptionally by stabilizing BMI1 protein to maintain cancer stem-like self-renewal and EMT, with BMI1 loss de-repressing IRF7 and Type I interferon signaling [#7, #8, #11]. In addition, BTF3 forms a complex with STAT3 and enhances its phosphorylation and downstream signaling [#14]. Beyond oncogenesis, BTF3a is induced by Mycobacterium tuberculosis in macrophages where it suppresses autophagic clearance of the pathogen [#15].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established BTF3 as a polypeptide that stably associates with RNA polymerase II and exists as two isoforms differing in transcriptional competence, defining its identity as a basal transcription-associated factor.\",\n      \"evidence\": \"Protein purification, cDNA cloning and in vitro complex formation assay defining BTF3a (active) versus BTF3b (inactive, pol II-binding)\",\n      \"pmids\": [\"2320128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis by which the N-terminal 44 residues confer transcriptional activity\", \"Did not map the contact surface with RNA pol II\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrated that the two isoforms arise by alternative splicing from a single seven-exon gene, explaining the molecular origin of BTF3a/BTF3b.\",\n      \"evidence\": \"Genomic cloning and sequence analysis of the BTF3 locus\",\n      \"pmids\": [\"1386332\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish how splicing between isoforms is regulated\", \"Promoter element function only inferred from sequence\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed via the yeast ortholog that BTF3-family proteins act as co-activators stabilizing transcription factor–DNA complexes, providing a conserved mechanistic role.\",\n      \"evidence\": \"Footprinting, gel retardation, purification and EGD1 gene disruption in yeast\",\n      \"pmids\": [\"1448098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether human BTF3 stabilizes specific activator–DNA complexes was not directly tested\", \"Direct DNA-binding contribution of BTF3 itself unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Refined the co-regulator picture by showing the redundant yeast homologs negatively regulate RNA pol II transcription specifically, distinguishing pol II from pol I/III targets.\",\n      \"evidence\": \"Double gene disruption (Egd1p/Btt1p) with mRNA expression profiling in yeast\",\n      \"pmids\": [\"8052529\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Activator versus repressor balance in human cells not addressed\", \"Mechanism of negative regulation not defined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Established BTF3 as essential for mammalian development, demonstrating a non-redundant in vivo requirement.\",\n      \"evidence\": \"Gene-trap insertional knockout in mice with embryo analysis showing E6.5 lethality\",\n      \"pmids\": [\"7655515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular cause of lethality not identified\", \"Specific developmental transcriptional targets unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified BTF3a as a CK2 substrate whose phosphorylation requires the CK2 \\u03b2 regulatory subunit, introducing post-translational regulation of BTF3.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown/co-IP and in vitro kinase assays with CK2 holoenzyme and subunits\",\n      \"pmids\": [\"10094400\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of CK2 phosphorylation on BTF3 activity untested\", \"Phosphosite(s) not mapped in vivo\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided the first cancer-context evidence that BTF3 functions as a transcriptional regulator of cancer-associated genes rather than a direct apoptosis modulator.\",\n      \"evidence\": \"siRNA knockdown with DNA microarray and apoptosis assays in pancreatic cancer cells\",\n      \"pmids\": [\"17312387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect transcriptional targets not distinguished\", \"No promoter-binding evidence\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked BTF3 to hormone-receptor signaling by showing it regulates ESR1/ER\\u03b1 transcription and modulates drug sensitivity in breast cancer.\",\n      \"evidence\": \"shRNA knockdown, reporter assays and in vitro/in vivo PI3K\\u03b1 inhibitor sensitivity in luminal breast cancer\",\n      \"pmids\": [\"30315845\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of BTF3 to the ESR1 promoter not shown\", \"Mechanism connecting BTF3 to PI3K pathway indirect\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a post-translational oncogenic mechanism: BTF3 stabilizes BMI1 protein to sustain cancer stem-like self-renewal and metastasis.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function with in vitro and in vivo stemness and tumorigenesis assays in prostate cancer\",\n      \"pmids\": [\"31138311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical basis of BMI1 stabilization not resolved\", \"Whether stabilization is direct binding or indirect\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Implicated STAT3 and stress-kinase signaling as downstream mediators of BTF3 in osteosarcoma.\",\n      \"evidence\": \"shRNA knockdown with signaling-array profiling and colony formation in Saos-2 cells\",\n      \"pmids\": [\"31205542\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Signaling-array associations lack mechanistic follow-up\", \"Direct versus indirect effects on each kinase undetermined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended BTF3 function beyond cancer, showing BTF3a is induced by M. tuberculosis and suppresses autophagic bacterial clearance in macrophages.\",\n      \"evidence\": \"CRISPR/Cas9 knockdown with autophagy flux, colocalization and CFU assays in THP-1 macrophages\",\n      \"pmids\": [\"30684544\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which BTF3 restrains autophagy unknown\", \"Transcriptional targets in macrophages not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected BTF3-driven stemness to immune evasion, showing BTF3 loss destabilizes BMI1 and de-represses IRF7/Type I interferon signaling.\",\n      \"evidence\": \"shRNA knockdown with western blot and reporter analysis in TNBC cells\",\n      \"pmids\": [\"33383560\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chromatin link from BMI1 to IRF7 not fully resolved here\", \"In vivo immune consequences not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Assigned isoform-specific function by showing BTF3b activates RFC subunit genes to support DNA replication and damage repair, with RFC3 epistasis confirming the axis.\",\n      \"evidence\": \"Isoform-specific overexpression/knockdown, reporter, cell cycle, DNA damage and cisplatin sensitivity assays\",\n      \"pmids\": [\"33414468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How transcriptionally inactive BTF3b activates RFC genes mechanistically unclear\", \"Direct promoter occupancy of RFC genes not detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified CHD1L as a direct transcriptional target and placed BTF3 within the NAC and a potential HERC2/p53 regulatory axis.\",\n      \"evidence\": \"RNA-seq + ChIP-seq for targets and IP-MS plus E3 ligase analysis for interactions\",\n      \"pmids\": [\"33644029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HERC2/p53 functional consequence not validated\", \"NAC interaction not functionally dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirmed BTF3 acts upstream of BMI1 to control stemness and EMT in a second cancer type, generalizing the BTF3–BMI1 axis.\",\n      \"evidence\": \"siRNA knockdown with BMI1 rescue, BMI1 inhibitor and stemness/EMT assays in colorectal cancer\",\n      \"pmids\": [\"34293363\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BTF3 controls BMI1 transcriptionally or post-translationally here not distinguished\", \"EMT mechanism downstream of BMI1 not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated BTF3 physically interacts with and transcriptionally activates FOXM1 to drive GLUT1-dependent glycolysis, linking BTF3 to tumor metabolism.\",\n      \"evidence\": \"Co-IP, dual-luciferase reporter, siRNA knockdown with FOXM1 rescue, extracellular flux and xenograft assays in HCC\",\n      \"pmids\": [\"37382415\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct BTF3 occupancy at the FOXM1 promoter versus co-factor role not fully separated\", \"Structural basis of BTF3–FOXM1 interaction unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed BTF3 forms a complex with STAT3 and promotes its phosphorylation to drive NLRP3-dependent pyroptosis, defining a direct BTF3–STAT3 signaling mechanism.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase, RIP, RNA pull-down and knockdown with flow cytometry in monocytes\",\n      \"pmids\": [\"38224186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How BTF3 enhances STAT3 phosphorylation mechanistically unresolved\", \"Kinase mediating the effect not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed PDCD2L as a BTF3 transcriptional target that restrains the p53 pathway to promote HCC proliferation.\",\n      \"evidence\": \"Knockdown with transcriptional and p53-pathway readouts plus proliferation/apoptosis assays\",\n      \"pmids\": [\"39707202\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"PDCD2L as a direct target not validated by ChIP or reporter\", \"Connection to p53 pathway largely correlative\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established lncRNA-guided chromatin recruitment, with LINC00622 directing BTF3 to the RRAGD promoter to activate mTORC1 and suppress autophagic cell death.\",\n      \"evidence\": \"ChIP, co-IP, reporter and loss-of-function with mTORC1 readout in melanoma models\",\n      \"pmids\": [\"40651979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of lncRNA-directed recruitment to other targets unknown\", \"Direct BTF3–LINC00622 binding interface not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified upstream regulation of BTF3 via RPL18-mediated mRNA stabilization feeding STAT3 activation and drug resistance in melanoma.\",\n      \"evidence\": \"Melanoma cell lines, organoids, xenografts, STAT3 inhibitor treatment and mRNA stability assays\",\n      \"pmids\": [\"41550725\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"mRNA-stabilization mechanism not rigorously resolved biochemically\", \"Directness of RPL18–BTF3 mRNA interaction unconfirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BTF3's canonical role as an RNA pol II-associated co-regulator and NAC component mechanistically connects to its diverse oncogenic transcriptional targets and post-translational stabilization of partners remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying structural model linking BTF3 chromatin recruitment to specific target selection\", \"The biochemical basis distinguishing BTF3a versus BTF3b target specificity is undefined\", \"Direct versus cofactor-mediated transcriptional activation not separated across most reported targets\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 9, 10, 13]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [14, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 10, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 10, 13]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 12, 13]}\n    ],\n    \"complexes\": [\"RNA polymerase II complex\", \"nascent-polypeptide-associated complex (NAC)\", \"BTF3/STAT3 complex\"],\n    \"partners\": [\"STAT3\", \"FOXM1\", \"BMI1\", \"CSNK2B\", \"HERC2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}